Canine Pheochromocytoma: Diagnosis and Comprehensive Management Strategies

Pheochromocytomas are neuroendocrine tumors originating from the chromaffin cells of the adrenal medulla, leading to the excessive secretion of catecholamines such as epinephrine and norepinephrine. While uncommon, these tumors are more frequently diagnosed in dogs than in cats and typically affect older animals. Understanding the etiology, clinical presentation, diagnostic approaches, and management strategies for canine pheochromocytoma is crucial for veterinary practitioners. This article provides an in-depth review of canine pheochromocytoma, aiming to enhance diagnostic accuracy and therapeutic outcomes.

Etiology and Pathophysiology of Canine Pheochromocytoma

Pheochromocytomas in dogs arise from the adrenal medulla, the inner part of the adrenal gland responsible for catecholamine production. These tumors are neuroendocrine in nature, meaning they involve both hormonal and nervous system functions. In most cases, pheochromocytomas are unilateral, affecting only one adrenal gland; however, bilateral involvement has been reported. Concurrent adrenocortical disease is a rare occurrence. Approximately half of canine pheochromocytomas exhibit malignant behavior, characterized by local invasion and metastasis. These tumors can invade major blood vessels like the caudal vena cava and spread to regional lymph nodes, liver, spleen, kidneys, lungs, and other organs.

Clinical Signs and Presentation

Many canine pheochromocytomas are incidental findings, discovered during necropsy without causing prior clinical signs. In fact, studies suggest that a significant percentage of dogs may have pheochromocytomas without exhibiting any symptoms during their lifetime. However, when clinical signs do manifest, they can be non-specific and intermittent, making diagnosis challenging. Common clinical signs include:

• Lethargy and Weakness: General fatigue and reduced activity levels.
• Weight Loss and Anorexia: Unexplained weight loss and decreased appetite.
• Panting: Excessive or inappropriate panting.
• Polydipsia and Polyuria (PU/PD): Increased thirst and urination.
• Abdominal Distention: Swelling or bloating of the abdomen.
• Collapse: Sudden episodes of weakness or loss of consciousness.

Additional clinical findings may include pale mucous membranes, tachycardia (rapid heart rate), and hypertension (high blood pressure). The variability and non-specificity of these signs underscore the importance of considering pheochromocytoma in the differential diagnosis for older dogs presenting with these symptoms.

Diagnostic Approaches for Canine Pheochromocytoma

Diagnosing canine pheochromocytoma involves a combination of clinical suspicion, imaging techniques, and specific laboratory tests.

General Laboratory Findings

Routine laboratory tests may reveal some abnormalities, although they are not always present or specific to pheochromocytoma. Potential findings include:

• Non-regenerative Anemia: Anemia associated with chronic disease processes.
• Regenerative Anemia: In cases of tumor hemorrhage.
• Hyperglycemia: Elevated blood glucose levels due to catecholamine effects.
• Elevated Liver Enzymes: Indicating potential liver involvement or secondary effects.
• Proteinuria and Variable Urine Concentration: May result from hypertension and the influence of catecholamines on vasopressin secretion.

Diagnostic Imaging

Imaging plays a crucial role in identifying adrenal masses and assessing tumor characteristics.

• Thoracic Radiographs: Typically used to rule out pulmonary metastasis.
• Abdominal Radiographs: May reveal a soft tissue mass in the adrenal region, although they can also be normal. Reduced serosal detail may be observed if hemorrhage has occurred.
• Abdominal Ultrasound: A highly sensitive tool for detecting adrenal masses, evaluating local invasion, and identifying concurrent thrombosis. Dogs with clinical signs are more likely to have larger tumors detectable via ultrasound.

Alt text: Abdominal ultrasound image showing a canine adrenal mass, indicative of potential pheochromocytoma, highlighting diagnostic imaging in veterinary medicine.

• Cross-sectional Imaging (CT/MRI): Computed tomography (CT) and magnetic resonance imaging (MRI) offer more detailed visualization of the adrenal glands and surrounding tissues, aiding in tumor detection and metastasis assessment. Contrast-enhanced CT is particularly useful in evaluating vascular involvement.
• Nuclear Scintigraphy with 123I-MIBG: Metaiodobenzylguanidine (MIBG) scintigraphy, using radiolabeled 123I-MIBG, has been utilized in human medicine to image neuroendocrine tumors. MIBG is taken up by neuroendocrine cells due to its structural similarity to norepinephrine. While less common in veterinary medicine, there are reports of successful pheochromocytoma visualization in dogs using 123I-MIBG and positron emission tomography (PET) with fluorinated MIBG.

Specific Diagnostic Tests

Definitive diagnosis often relies on specialized tests to confirm excessive catecholamine production.

• Plasma and Urine Catecholamines and Metanephrines: In human medicine, measuring catecholamines (norepinephrine, epinephrine, dopamine) and their metabolites (metanephrine, normetanephrine, vanillylmandelic acid) in urine or plasma using High-Performance Liquid Chromatography (HPLC) is standard for pheochromocytoma diagnosis. However, in veterinary medicine, this testing is not routinely performed due to limited availability, episodic catecholamine release (leading to poor test sensitivity), and a lack of established normal ranges for dogs. Recent studies have explored urinary catecholamine and metabolite ratios in dogs, suggesting that urinary normetanephrine:creatinine ratios may be significantly higher in dogs with pheochromocytomas compared to healthy dogs. Plasma metanephrine and normetanephrine levels are also being investigated as potential diagnostic markers in dogs.

• Chromogranin A Measurement: Chromogranin A is a peptide stored and released with catecholamines and other hormones. Human ELISA assays have been adapted for canine plasma samples to measure chromogranin A, showing promising results, but further research is needed to validate its clinical utility in diagnosing canine pheochromocytoma.

• Histopathology and Immunohistochemistry: The gold standard for definitive diagnosis is histopathological examination of the adrenal tumor tissue after surgical removal. Immunohistochemical staining for chromogranin A and synaptophysin, proteins expressed by neuroendocrine tumors, further confirms the diagnosis. Synaptophysin, a membrane glycoprotein found in presynaptic vesicles of neurons and neuroendocrine cells, serves as an additional marker.

Management and Treatment Strategies

Adrenalectomy, surgical removal of the adrenal gland, is the treatment of choice for canine pheochromocytoma when clinical signs are present and the tumor is resectable.

Pre-operative Management

Pre-surgical stabilization is critical, particularly addressing hypertension and tachyarrhythmias associated with excessive catecholamine release.

• Alpha-Adrenergic Blockade: Phenoxybenzamine, a non-specific alpha-antagonist, is administered pre-operatively to control hypertension. Treatment typically starts 14 to 21 days before surgery to achieve stable blood pressure. Alpha-blockade helps prevent hypertensive crises during surgery and anesthesia.
• Beta-Adrenergic Blockade: If tachycardia is present, beta-blockers such as atenolol or propranolol are added. It is crucial to initiate beta-blocker therapy several days after starting phenoxybenzamine to avoid severe hypertension resulting from unopposed alpha-adrenergic receptor stimulation.

Pre-operative phenoxybenzamine treatment has been shown to significantly decrease mortality in dogs undergoing adrenalectomy for pheochromocytoma.

Surgical Considerations

Surgical removal of pheochromocytoma is technically challenging due to the tumor’s location and potential vascular invasion.

• Adrenalectomy Techniques: Careful surgical technique is essential to minimize complications such as hemorrhage and cardiovascular instability. Venotomy may be necessary to remove tumor thrombi extending into major vessels, and vascular resection may be required for tumors invading blood vessels.
• Anesthetic Management: Anesthesia protocols require careful consideration. Morphine is avoided due to histamine release and potential hypotension. Ketamine, a sympathomimetic agent, is also contraindicated. Halothane may sensitize the myocardium to arrhythmias. Anesthetic agents and monitoring should be tailored to manage potential intra-operative and post-operative complications, including arrhythmias, hypertension, hypotension, and hemorrhage.

Management of Non-Resectable or Metastatic Disease

In cases with local invasion or metastasis where complete surgical resection is not feasible, palliative strategies are employed.

• Surgical Debulking: Partial tumor removal may be performed to reduce tumor burden and alleviate clinical signs.
• Medical Management: Phenoxybenzamine and beta-blockers can be used long-term to manage hypertension and arrhythmias when surgical resection is not possible or complete.

Prognosis for Canine Pheochromocytoma

The prognosis for canine pheochromocytoma following complete surgical resection is generally good. Even with incomplete resection or in cases managed medically, survival times of several years have been reported, particularly with effective management of hypertension and arrhythmias.

References

1. Nelson RW, Feldman EC. Pheochromocytoma and Multiple Endocrine Neoplasia in Canine and Feline Endocrinology and Reproduction 3rd ed. Nelson RW, Feldman EC (eds) Saunders 2004. p. 440 – 458.
2. Fitzgerald PA, Goldfien A. Adrenal Medulla in Basic and Clinical Endocrinology 7th ed Greenspan FS, Gardner DG (eds) Lange 2004. pp. 439-51.
3. Wimpole JA, Adagra CF, et al. Plasma free metanephrines in healthy cats, cats with non-adrenal disease and a cat with suspected pheochromocytoma. J feline Med Surg 2010 June; 12(6):435-40.
4. Calsyn JD, Green RA, et al. Adrenal pheochromocytoma with contralateral adrenocortical adenoma in a cat. J Am Anim Hosp Assoc 2010 Jan-Feb;46(1):36-42.
5. Chun R, Jakovijevic S, et al. Apocrine gland adenocarcinoma and pheochromocytoma in a cat. J AM Anim Hosp Assoc 1997 Jan-Feb;33(1):33-6.
6. Henry CJ, Brewer WG, jr, et al. Clinical vignette. Adrenal pheochromocytoma. J Vet Int Med. 1993 May-Jun;7(3):199-201.
7. Barthez PY, Marks SL, et al. Pheochromocytoma in dogs:61 cases (1984-1995) J Vet Int Med 1997 Sept-Oct;11(5)272-8.
8. Gilson SD, Withrow SJ, et al. Pheochromocytoma in 50 dogs J Vet Intern Med 1994 May-Jun; 23(3):195-200
9. Hylands R. Veterinary diagnostic imaging: Malignant pheochromocytoma of the left adrenal gland invading the caudal vena cava accompanied by a cortisol-secreting adrenocortical carcinoma of the right adrenal gland. Can Vet J 2005 Dec;46(12):1156-8.
10. Thuroczy J, van Sluijs FJ, et al. Multiple endocrine neoplasia in a dog: corticotrophic tumor, bilateral adrenocortical tumors, and pheochromocytoma. Vet Q. 1999 Apr;20(2):56-61.
11. Von Dehn BJ, Nelson RW, et al. Pheochromocytoma and hyperadrenocorticism in dogs: six cases (1982-1992). J Am Vet Med Assoc 1995 Aug;1:207(3):322-4.
12. Kyles AE, Feldman EC, et al. Surgical management of adrenal gland tumors with and without associated tumor thrombi in dogs: 40 cases (1994-2001). J Am Vet Med Assoc 2003 Sep 1;223(5):654-62.
13. Platt SR, Sheppard BJ, et al. Pheochromocytoma in the vertebral canal of two dogs. J Am Anim Hosp Assoc 1998 Sep-Oct;34(5):365-71.
14. Boes K, Zimmerman K, et al. What is your diagnosis? Shoulder mass in a dog with lameness. Vet Clin Pathol 2009 Dec;36(4):511-15.
15. Schulz RM, Wisner ER, et al. Contrast-enhanced computed tomography as a preoperative indicator of vascular masses from adrenal masses in dogs. Vet Radiol Ultrasound 2009 Nov-Dec;50(6):625-9.
16. Jacobson AF, Deng H, et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of meta-analysis. J Clin Endocrinol Metab 2010 Jun;95(6):2596-606.
17. Wright KM,N, Breitschwerdt EB, et al. Diagnostic and therapeutic considerations in a hypercalcemic dog with multiple endocrine neoplasia. J Am Anim Hosp Assoc 1995 Mar-Apr;31(2):156-62.
18. Berry CR, DeGrado TR, et al. Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. Vet Radiol Ultrasound 2002 Mar-Apr;43(2):183-6.
19. Lenders JW, Pacak K, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002 Mar 20;287(11):1427-34.
20. Kook PH, Grest PL, et al. Urinary catecholamine and metadrenaline to creatinine ratios in dogs with phaeochromocytoma. Vet Rec 2010 Feb 6;166(6):169-74.
21. Gostelow R, Syme H. Plasma metadrenalines in canine pheochromocytoma. Vet Rec 2010 Apr 24;166(17):538.
22. Akiyoshi H, Aoki M, et al. Measurement of plasma chromogranin A concentrations for assessment of stress responses in dogs with insulin-induced hypoglycemia. Am J Vet Res 2005 Oct;66(10):1830-5.
23. Doss, JC, Grone A, et al. Immunohistochemical localization of chromogranin A in endocrine tissues and endocrine tumors of dogs. Vet Pathol 1998 Jul;35(4):312-25.
24. Gould VE, Wiedenmann B, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol 1987 Feb;126(2):243-57.
25. Fossum TW. The Endocrine System in Small Animal Surgery 3rd ed. Fossuw TW (ed) Elsevier 2007. pp. 578-84.
26. Herrara MA, Mehl ML, et al. Predictive factors and the effect of phenoxybenzamine on outcome in dogs undergoing adrenalectomy for pheochromocytoma. J Vet Int Med 2008 Nov-Dec;22(6):1333-9
27. Robertson SA. Anesthesia in Textbook of Small Animal Surgery 3rd ed. Slatter D (ed) Saunders 2003. p. 2590-1.
28. Bailey DB, Page RL. Tumors of the Endocrine System in Withrow and MacEwan’s Small Animal Clinical Oncology 4th ed. Withrow SJ, Vail DM (eds.) Saunders 2007. pp. 590-1.